Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead

BACKGROUND: Combined-modality therapy is a promising approach to improve the therapeutic index of radiotherapy. However, these improvements could come at the cost of increased toxicities. Clinical trials evaluating anti-tumour efficacy of bevacizumab combined with radiotherapy have encountered unexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangoni, M, Vozenin, M-C, Biti, G, Deutsch, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394974/
https://www.ncbi.nlm.nih.gov/pubmed/22691970
http://dx.doi.org/10.1038/bjc.2012.236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394974/
https://www.ncbi.nlm.nih.gov/pubmed/22691970
http://dx.doi.org/10.1038/bjc.2012.236

Ejemplares similares